Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSTA-MD: Minocycline and Celecoxib in Depression
NCT05644301Phase 3Recruiting
- Sponsor
- University of Antwerp
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of minocycline and celecoxib oral solution in major depressive disorder (MDD) (6 arms), sponsored by University of Antwerp. Primary endpoints: Change in depressive symptom severity (Hamilton Depression Rating Scale-17) at 12 weeks and Remission rate of depression (HDRS-17) at 12 weeks. Started Sep 2023; status: recruiting.
02
Drugs
minocyclinecelecoxib oral solution
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05644301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05644301.